Lab
Vitality DX LLC
Vitality DX LLC was paid $2.05M by Medicaid between Nov 2020 and May 2023, across 32 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 51% of everything it billed.
33Billing provider infoVITALITY DX LLC
LEXINGTON, KY 40505
LEXINGTON, KY 40505
33aNPI1386246858assigned 11/10/2020
33bProvider typeClinical Medical Laboratory
28Total paid$2.05M
24GClaims41,403
24DCodes billed32
24AFirst – last monthNov 2020 – May 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in Kentucky
Rank by total paid#18 of 73
Median peer was paid$95K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FISHER, TAMIA controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 3,480 | $86K | |
| 2021 | 28,638 | $1.41M | |
| 2022 | 8,066 | $441K | |
| 2023 | 1,219 | $120K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 51% | 14,710 | 4,689 | $1.04M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 21% | 8,125 | 3,284 | $426K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 11% | 3,195 | 1,952 | $226K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 8.4% | 4,443 | 2,670 | $172K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.2% | 1,405 | 1,175 | $66K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 875 | 692 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,999 | 1,138 | $20K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 596 | 561 | $15K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,927 | 1,205 | $15K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,062 | 1,029 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,060 | 1,027 | $13K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,060 | 1,027 | $13K |
20 more codes
| 87631 | <1% | 63 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 15 | $3K |
| 86413 | <1% | 194 | $3K | |
| 86409 | <1% | 179 | $2K | |
| 87640 | <1% | 74 | $266.76 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 23 | $227.50 |
| 81025 | <1% | 22 | $73.74 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 72 | $10.56 |
| 86022 | <1% | 31 | $8.96 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 19 | $0.00 |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 25 | $0.00 |
| 85018 | 0% | 30 | $0.00 | |
| 80053 | Comprehensive metabolic panel | 0% | 40 | $0.00 |
| 85027 | 0% | 32 | $0.00 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 17 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 19 | $0.00 |
| 85014 | 0% | 30 | $0.00 | |
| 85049 | 0% | 30 | $0.00 | |
| 85041 | 0% | 15 | $0.00 | |
| 80061 | Lipid panel | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFISHER, TAMIA (CREDENTIALING)
| Provider | Location | Paid |
|---|---|---|
| Interventional Pain & Spine Specialists LLC | Lexington, KY | $6.25M |
| Commonwealth Pain Specialists, PLLC | Frankfort, KY | $2.14M |
| Interventional Pain & Spine Specialists LLC | Lexington, KY | $1.22M |
| Interventional Pain & Spine Specialists LLC | Evansville, IN | $522K |
| Interventional Pain & Spine Specialists, LLC | Louisville, KY | $462K |
| Interventional Pain & Spine Specialists LLC | Bowling Green, KY | $374K |
| Interventional Pain & Spine Specialists LLC | Louisville, KY | $323K |
| Interventional Pain & Spine Specialists LLC | Bowling Green, KY | $308K |
| Interventional Pain & Spine Specialists LLC | Frankfort, KY | $177K |
| Interventional Pain & Spine Specialists LLC | Louisville, KY | $136K |
| Vitality Pain Management LLC | Bowling Green, KY | $116K |
| X-Gene Molecular Laboratories, INC | Louisville, KY | $50K |
| Kingdom Counseling | Chandler, IN | $7K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.